carnitine has been researched along with Polycystic Ovary Syndrome in 25 studies
Polycystic Ovary Syndrome: A complex disorder characterized by infertility, HIRSUTISM; OBESITY; and various menstrual disturbances such as OLIGOMENORRHEA; AMENORRHEA; ANOVULATION. Polycystic ovary syndrome is usually associated with bilateral enlarged ovaries studded with atretic follicles, not with cysts. The term, polycystic ovary, is misleading.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our result showed that oral L-Carnitine administration during induction of ovulation among PCOS women could not improve laboratory and pregnancy outcome." | 9.69 | The effect of adding L-Carnitine to the GnRH-antagonist protocol on assisted reproductive technology outcome in women with polycystic ovarian syndrome: a randomized clinical trial. ( Davar, R; Eftekhar, M; Sheida, A; Tabibnejad, N, 2023) |
| "12-week L-carnitine supplementation in overweight or obese women with PCOS ameliorate insulin resistance, but has no effect on SHBG and lipid profile." | 9.51 | The effect of L-carnitine supplementation on insulin resistance, sex hormone-binding globulin and lipid profile in overweight/obese women with polycystic ovary syndrome: a randomized clinical trial. ( Fallahzadeh, H; Ghadiri-Anari, A; Hosseinzadeh, M; Nadjarzadeh, A; Pakravanfar, F; Sangouni, AA, 2022) |
| "The present study aimed to investigate the effect of l-carnitine supplementation on liver fat content and cardiometabolic outcomes in overweight/obese women with PCOS." | 9.41 | Effect of l-carnitine supplementation on liver fat content and cardiometabolic indices in overweight/obese women with polycystic ovary syndrome: A randomized controlled trial. ( Ghadiri-Anari, A; Hosseinzadeh, M; Sangouni, AA; Sasanfar, B, 2021) |
| "With the available literature, carnitine seems to improve ovulation and clinical pregnancy and insulin resistance, BMI in women with PCOS." | 9.41 | Effects of carnitine on glucose and lipid metabolic profiles and fertility outcomes in women with polycystic ovary syndrome: A systematic review and meta-analysis. ( Cai, Q; Gong, Y; He, H; Jiang, T; Li, J; Shen, R; Shi, Y; Wang, Y; Wu, GL; Xiong, CL, 2023) |
| "To compare clinical and metabolic profiles between N-acetylcysteine and l-carnitine among women with clomiphene citrate (CC)-resistant polycystic ovary syndrome (PCOS)." | 9.30 | Randomized controlled trial of N-acetylcysteine versus l-carnitine among women with clomiphene-citrate-resistant polycystic ovary syndrome. ( Abd El Aziz, WM; El Sharkwy, IA, 2019) |
| "Limited data are available assessing the effects of oral carnitine supplementation on mental health parameters and biomarkers of oxidative stress of women with polycystic ovary syndrome (PCOS)." | 9.24 | Oral carnitine supplementation influences mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. ( Afshar Ebrahimi, F; Aghababayan, S; Asemi, Z; Bahmani, F; Jamilian, H; Jamilian, M; Kouhi, M; Rahimi, M; Samimi, M; Shahabbaspour, S, 2017) |
| "In a prospective, randomized, double-blind, placebo-controlled trial, 60 overweight patients diagnosed with PCOS were randomized to receive either 250 mg carnitine supplements (n = 30) or placebo (n = 30) for 12 weeks." | 9.22 | Oral carnitine supplementation reduces body weight and insulin resistance in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. ( Asemi, Z; Ebrahimi, FA; Jamilian, M; Rahimi, M; Samimi, M; Tajbakhsh, B, 2016) |
| "To evaluate the effectiveness of L-carnitine on improving the ovulation and pregnancy rates as well as adverse metabolic indices in clomiphene-resistant PCOS." | 9.19 | Adding L-carnitine to clomiphene resistant PCOS women improves the quality of ovulation and the pregnancy rate. A randomized clinical trial. ( Hamed, AH; Ismail, AM; Saso, S; Thabet, HH, 2014) |
| "To determine fasting and insulin-stimulated levels of carnitine precursors, total and free carnitine, and acylcarnitines, and evaluate the impact of pioglitazone treatment in obese patients with polycystic ovary syndrome (PCOS)." | 9.16 | Free carnitine and acylcarnitines in obese patients with polycystic ovary syndrome and effects of pioglitazone treatment. ( Berge, RK; Bjørndal, B; Bohov, P; Gaster, M; Glintborg, D; Nygård, O; Seifert, R; Svardal, A; Vigerust, NF, 2012) |
| "Polycystic ovary syndrome (PCOS) is related to low levels of serum l-carnitine, which has antioxidant, anti-inflammatory and antiapoptotic properties." | 7.91 | L-Carnitine improves endocrine function and folliculogenesis by reducing inflammation, oxidative stress and apoptosis in mice following induction of polycystic ovary syndrome. ( Azadbakht, M; Kalhori, Z; Mehranjani, MS; Shariatzadeh, MA, 2019) |
| " Blood samples were taken after overnight fasting at baseline and three months into the study to assess the levels of fasting glucose, insulin, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), free testosterone, dehydroepiandrosterone (DHEA), and the insulin resistance index (HOMA-IR)." | 7.91 | Effects of L-carnitine on Polycystic Ovary Syndrome. ( Gachkar, L; Hoseini, S; Moghaddam, PB; Nazari, L; Salehpour, S, 2019) |
| "Decreased total L-carnitine levels may be associated with hyperandrogenism and/or insulin resistance in non-obese women with PCOS." | 7.74 | Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome. ( Fenkci, SM; Fenkci, V; Karagenc, N; Oztekin, O; Rota, S, 2008) |
| "Our result showed that oral L-Carnitine administration during induction of ovulation among PCOS women could not improve laboratory and pregnancy outcome." | 5.69 | The effect of adding L-Carnitine to the GnRH-antagonist protocol on assisted reproductive technology outcome in women with polycystic ovarian syndrome: a randomized clinical trial. ( Davar, R; Eftekhar, M; Sheida, A; Tabibnejad, N, 2023) |
| "12-week L-carnitine supplementation in overweight or obese women with PCOS ameliorate insulin resistance, but has no effect on SHBG and lipid profile." | 5.51 | The effect of L-carnitine supplementation on insulin resistance, sex hormone-binding globulin and lipid profile in overweight/obese women with polycystic ovary syndrome: a randomized clinical trial. ( Fallahzadeh, H; Ghadiri-Anari, A; Hosseinzadeh, M; Nadjarzadeh, A; Pakravanfar, F; Sangouni, AA, 2022) |
| "The present study aimed to investigate the effect of l-carnitine supplementation on liver fat content and cardiometabolic outcomes in overweight/obese women with PCOS." | 5.41 | Effect of l-carnitine supplementation on liver fat content and cardiometabolic indices in overweight/obese women with polycystic ovary syndrome: A randomized controlled trial. ( Ghadiri-Anari, A; Hosseinzadeh, M; Sangouni, AA; Sasanfar, B, 2021) |
| "With the available literature, carnitine seems to improve ovulation and clinical pregnancy and insulin resistance, BMI in women with PCOS." | 5.41 | Effects of carnitine on glucose and lipid metabolic profiles and fertility outcomes in women with polycystic ovary syndrome: A systematic review and meta-analysis. ( Cai, Q; Gong, Y; He, H; Jiang, T; Li, J; Shen, R; Shi, Y; Wang, Y; Wu, GL; Xiong, CL, 2023) |
| "To evaluate the reproductive and metabolic effects of L-carnitine plus metformin in clomiphene citrate (CC) resistant obese polycystic ovary syndrome (PCOS) women." | 5.30 | l-Carnitine plus metformin in clomiphene-resistant obese PCOS women, reproductive and metabolic effects: a randomized clinical trial. ( El Sharkwy, I; Sharaf El-Din, M, 2019) |
| "To compare clinical and metabolic profiles between N-acetylcysteine and l-carnitine among women with clomiphene citrate (CC)-resistant polycystic ovary syndrome (PCOS)." | 5.30 | Randomized controlled trial of N-acetylcysteine versus l-carnitine among women with clomiphene-citrate-resistant polycystic ovary syndrome. ( Abd El Aziz, WM; El Sharkwy, IA, 2019) |
| "Limited data are available assessing the effects of oral carnitine supplementation on mental health parameters and biomarkers of oxidative stress of women with polycystic ovary syndrome (PCOS)." | 5.24 | Oral carnitine supplementation influences mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. ( Afshar Ebrahimi, F; Aghababayan, S; Asemi, Z; Bahmani, F; Jamilian, H; Jamilian, M; Kouhi, M; Rahimi, M; Samimi, M; Shahabbaspour, S, 2017) |
| "In a prospective, randomized, double-blind, placebo-controlled trial, 60 overweight patients diagnosed with PCOS were randomized to receive either 250 mg carnitine supplements (n = 30) or placebo (n = 30) for 12 weeks." | 5.22 | Oral carnitine supplementation reduces body weight and insulin resistance in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. ( Asemi, Z; Ebrahimi, FA; Jamilian, M; Rahimi, M; Samimi, M; Tajbakhsh, B, 2016) |
| "To evaluate the effectiveness of L-carnitine on improving the ovulation and pregnancy rates as well as adverse metabolic indices in clomiphene-resistant PCOS." | 5.19 | Adding L-carnitine to clomiphene resistant PCOS women improves the quality of ovulation and the pregnancy rate. A randomized clinical trial. ( Hamed, AH; Ismail, AM; Saso, S; Thabet, HH, 2014) |
| "To determine fasting and insulin-stimulated levels of carnitine precursors, total and free carnitine, and acylcarnitines, and evaluate the impact of pioglitazone treatment in obese patients with polycystic ovary syndrome (PCOS)." | 5.16 | Free carnitine and acylcarnitines in obese patients with polycystic ovary syndrome and effects of pioglitazone treatment. ( Berge, RK; Bjørndal, B; Bohov, P; Gaster, M; Glintborg, D; Nygård, O; Seifert, R; Svardal, A; Vigerust, NF, 2012) |
| " IR in adults with obesity and diabetes is associated with changes in amino acid, free fatty acid (FFA), and mitochondrial acylcarnitine (AC) metabolism." | 3.91 | Amino acid and fatty acid metabolomic profile during fasting and hyperinsulinemia in girls with polycystic ovarian syndrome. ( Bergman, BC; Carreau, AM; Cree-Green, M; Garcia-Reyes, Y; Nadeau, KJ; Pyle, L; Rahat, H, 2019) |
| "Polycystic ovary syndrome (PCOS) is related to low levels of serum l-carnitine, which has antioxidant, anti-inflammatory and antiapoptotic properties." | 3.91 | L-Carnitine improves endocrine function and folliculogenesis by reducing inflammation, oxidative stress and apoptosis in mice following induction of polycystic ovary syndrome. ( Azadbakht, M; Kalhori, Z; Mehranjani, MS; Shariatzadeh, MA, 2019) |
| " Blood samples were taken after overnight fasting at baseline and three months into the study to assess the levels of fasting glucose, insulin, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), free testosterone, dehydroepiandrosterone (DHEA), and the insulin resistance index (HOMA-IR)." | 3.91 | Effects of L-carnitine on Polycystic Ovary Syndrome. ( Gachkar, L; Hoseini, S; Moghaddam, PB; Nazari, L; Salehpour, S, 2019) |
| "Decreased total L-carnitine levels may be associated with hyperandrogenism and/or insulin resistance in non-obese women with PCOS." | 3.74 | Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome. ( Fenkci, SM; Fenkci, V; Karagenc, N; Oztekin, O; Rota, S, 2008) |
| "Carnitine was relatively effective in reducing body mass, while chromium, Omega-3, and selenium were beneficial for improving glucose metabolism." | 3.01 | Comparison of nutritional supplements in improving glycolipid metabolism and endocrine function in polycystic ovary syndrome: a systematic review and network meta-analysis. ( Hu, X; Huang, Y; Li, Y; Peng, H; Su, X; Tan, Z; Wang, W, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.00) | 29.6817 |
| 2010's | 15 (60.00) | 24.3611 |
| 2020's | 9 (36.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liao, D | 1 |
| Liu, X | 1 |
| Yuan, X | 1 |
| Feng, P | 1 |
| Ouyang, Z | 1 |
| Liu, Y | 2 |
| Li, C | 1 |
| Sangouni, AA | 2 |
| Pakravanfar, F | 1 |
| Ghadiri-Anari, A | 2 |
| Nadjarzadeh, A | 1 |
| Fallahzadeh, H | 1 |
| Hosseinzadeh, M | 2 |
| Sasanfar, B | 1 |
| Guan, SY | 1 |
| Liu, YY | 1 |
| Guo, Y | 1 |
| Shen, XX | 1 |
| Jin, HX | 1 |
| Gong, Y | 1 |
| Jiang, T | 1 |
| He, H | 1 |
| Wang, Y | 2 |
| Wu, GL | 1 |
| Shi, Y | 1 |
| Cai, Q | 1 |
| Xiong, CL | 1 |
| Shen, R | 1 |
| Li, J | 2 |
| Hu, X | 1 |
| Wang, W | 1 |
| Su, X | 1 |
| Peng, H | 1 |
| Tan, Z | 1 |
| Li, Y | 1 |
| Huang, Y | 1 |
| Eyupoglu, ND | 1 |
| Caliskan Guzelce, E | 1 |
| Acikgoz, A | 1 |
| Uyanik, E | 1 |
| Bjørndal, B | 2 |
| Berge, RK | 2 |
| Svardal, A | 2 |
| Yildiz, BO | 1 |
| Sheida, A | 1 |
| Davar, R | 1 |
| Tabibnejad, N | 1 |
| Eftekhar, M | 1 |
| Zhao, X | 2 |
| Feng, X | 1 |
| Jiang, Y | 1 |
| Li, X | 1 |
| Niu, J | 1 |
| Meng, X | 1 |
| Wu, J | 1 |
| Xu, G | 1 |
| Hou, L | 1 |
| Jia, C | 1 |
| Xu, H | 1 |
| Xu, Y | 2 |
| Shi, Q | 1 |
| Cree-Green, M | 1 |
| Carreau, AM | 1 |
| Rahat, H | 1 |
| Garcia-Reyes, Y | 1 |
| Bergman, BC | 1 |
| Pyle, L | 1 |
| Nadeau, KJ | 1 |
| El Sharkwy, I | 1 |
| Sharaf El-Din, M | 1 |
| Maleki, V | 1 |
| Jafari-Vayghan, H | 1 |
| Kashani, A | 1 |
| Moradi, F | 1 |
| Vajdi, M | 1 |
| Kheirouri, S | 1 |
| Alizadeh, M | 1 |
| Jamilian, M | 3 |
| Foroozanfard, F | 1 |
| Kavossian, E | 1 |
| Kia, M | 1 |
| Aghadavod, E | 1 |
| Amirani, E | 1 |
| Asemi, Z | 3 |
| Kalhori, Z | 1 |
| Mehranjani, MS | 1 |
| Azadbakht, M | 1 |
| Shariatzadeh, MA | 1 |
| El Sharkwy, IA | 1 |
| Abd El Aziz, WM | 1 |
| Salehpour, S | 1 |
| Nazari, L | 1 |
| Hoseini, S | 1 |
| Moghaddam, PB | 1 |
| Gachkar, L | 1 |
| Ismail, AM | 1 |
| Hamed, AH | 1 |
| Saso, S | 1 |
| Thabet, HH | 1 |
| Zhao, H | 1 |
| Zhao, Y | 1 |
| Li, T | 1 |
| Li, M | 1 |
| Li, R | 1 |
| Liu, P | 1 |
| Yu, Y | 1 |
| Qiao, J | 1 |
| Samimi, M | 2 |
| Ebrahimi, FA | 1 |
| Rahimi, M | 2 |
| Tajbakhsh, B | 1 |
| Chen, YX | 1 |
| Zhang, XJ | 1 |
| Huang, J | 1 |
| Zhou, SJ | 1 |
| Liu, F | 1 |
| Jiang, LL | 1 |
| Chen, M | 1 |
| Wan, JB | 1 |
| Yang, DZ | 1 |
| Celik, F | 1 |
| Kose, M | 1 |
| Yilmazer, M | 1 |
| Köken, GN | 1 |
| Arioz, DT | 1 |
| Kanat Pektas, M | 1 |
| Jamilian, H | 1 |
| Afshar Ebrahimi, F | 1 |
| Bahmani, F | 1 |
| Aghababayan, S | 1 |
| Kouhi, M | 1 |
| Shahabbaspour, S | 1 |
| Vigerust, NF | 1 |
| Bohov, P | 1 |
| Seifert, R | 1 |
| Nygård, O | 1 |
| Glintborg, D | 1 |
| Gaster, M | 1 |
| Fenkci, SM | 1 |
| Fenkci, V | 1 |
| Oztekin, O | 1 |
| Rota, S | 1 |
| Karagenc, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| N-Acetylcysteine Versus L-carnitine in Clomiphene Citrate Resistant Pcos Women. a Randomized Controlled Trial[NCT03164421] | Phase 2 | 164 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| The Effects of Acetyl L--Carnitine and Myo/Chiro-Inositol on Improving Ovulation, Pregnancy Rate, Ovarian Function and Perceived Stress Response in Patients With PCOS[NCT05767515] | 120 participants (Anticipated) | Interventional | 2023-04-15 | Not yet recruiting | |||
| Effects of Triple Drug Cocktail Therapy on Metabolic, Endocrine Alterations and Perceived Stress Response in Patients With PCOS: A Double Blind Randomized Clinical Trial[NCT04113889] | Phase 2 | 147 participants (Actual) | Interventional | 2019-10-15 | Completed | ||
| The Effect of PPARgamma Stimulation on Glucose Metabolism, Insulin Resistance, Growth Hormone and Cortisol on Women Suffering From Polycystic Ovary Syndrome[NCT00145340] | Phase 4 | 30 participants | Interventional | 2002-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for carnitine and Polycystic Ovary Syndrome
| Article | Year |
|---|---|
Clinical evidence of the effects of carnitine supplementation on body weight, glycemic control and serum lipids in women with polycystic ovary syndrome: a systematic review and meta-analysis.
Topics: Body Weight; Carnitine; Dietary Supplements; Female; Glycemic Control; Humans; Polycystic Ovary Synd | 2022 |
Effects of carnitine on glucose and lipid metabolic profiles and fertility outcomes in women with polycystic ovary syndrome: A systematic review and meta-analysis.
Topics: Carnitine; Cholesterol; Female; Fertility; Glucose; Humans; Insulin; Insulin Resistance; Lipids; Lip | 2023 |
Comparison of nutritional supplements in improving glycolipid metabolism and endocrine function in polycystic ovary syndrome: a systematic review and network meta-analysis.
Topics: Carnitine; Cholesterol, HDL; Chromium; Female; Glycolipids; Humans; Lipid Metabolism; Network Meta-A | 2023 |
Potential roles of carnitine in patients with polycystic ovary syndrome: a systematic review.
Topics: Blood Glucose; Body Mass Index; Carnitine; Female; Humans; Insulin Resistance; Oxidative Stress; Pol | 2019 |
10 trials available for carnitine and Polycystic Ovary Syndrome
| Article | Year |
|---|---|
The effect of L-carnitine supplementation on insulin resistance, sex hormone-binding globulin and lipid profile in overweight/obese women with polycystic ovary syndrome: a randomized clinical trial.
Topics: Carnitine; Cholesterol, HDL; Dietary Supplements; Double-Blind Method; Female; Humans; Insulin; Insu | 2022 |
Effect of l-carnitine supplementation on liver fat content and cardiometabolic indices in overweight/obese women with polycystic ovary syndrome: A randomized controlled trial.
Topics: Cardiovascular Diseases; Carnitine; Dietary Supplements; Female; Humans; Iran; Liver; Obesity; Overw | 2021 |
The effect of adding L-Carnitine to the GnRH-antagonist protocol on assisted reproductive technology outcome in women with polycystic ovarian syndrome: a randomized clinical trial.
Topics: Carnitine; Female; Gonadotropin-Releasing Hormone; Humans; Ovulation Induction; Polycystic Ovary Syn | 2023 |
l-Carnitine plus metformin in clomiphene-resistant obese PCOS women, reproductive and metabolic effects: a randomized clinical trial.
Topics: Adult; Blood Glucose; Carnitine; Clomiphene; Drug Resistance; Female; Fertility Agents, Female; Horm | 2019 |
Effects of Chromium and Carnitine Co-supplementation on Body Weight and Metabolic Profiles in Overweight and Obese Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Adult; Body Weight; Carnitine; Chromium; Dietary Supplements; Double-Blind Method; Female; Gene Expr | 2020 |
Randomized controlled trial of N-acetylcysteine versus l-carnitine among women with clomiphene-citrate-resistant polycystic ovary syndrome.
Topics: Acetylcysteine; Adult; Carnitine; Clomiphene; Double-Blind Method; Female; Follicle Stimulating Horm | 2019 |
Adding L-carnitine to clomiphene resistant PCOS women improves the quality of ovulation and the pregnancy rate. A randomized clinical trial.
Topics: Adult; Carnitine; Clomiphene; Double-Blind Method; Drug Resistance; Drug Synergism; Drug Therapy, Co | 2014 |
Oral carnitine supplementation reduces body weight and insulin resistance in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Blood Glucose; Body Weights and Measures; Carnitine; Dietar | 2016 |
Oral carnitine supplementation influences mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Carnitine; Dietary Supplements; Double-Blind Method; Female; Humans; Oxidative Stress; Polycy | 2017 |
Free carnitine and acylcarnitines in obese patients with polycystic ovary syndrome and effects of pioglitazone treatment.
Topics: Adult; Carnitine; Female; Humans; Hypoglycemic Agents; Obesity; Pioglitazone; Polycystic Ovary Syndr | 2012 |
11 other studies available for carnitine and Polycystic Ovary Syndrome
| Article | Year |
|---|---|
Potential biomarkers for clinical outcomes of IVF cycles in women with/without PCOS: Searching with metabolomics.
Topics: Biomarkers; Carnitine; Female; Fertilization in Vitro; Glycerol; Humans; Phospholipids; Polycystic O | 2022 |
Circulating gut microbiota metabolite trimethylamine N-oxide and oral contraceptive use in polycystic ovary syndrome.
Topics: Adolescent; Adult; Betaine; Blood Glucose; Cardiovascular Diseases; Carnitine; Choline; Female; Gast | 2019 |
How to Screen and Prevent Metabolic Syndrome in Patients of PCOS Early: Implications From Metabolomics.
Topics: Adolescent; Adult; Biomarkers; Carnitine; Female; Glutamic Acid; Humans; Leucine; Metabolic Syndrome | 2021 |
Serum metabolomics analysis of patients with polycystic ovary syndrome by mass spectrometry.
Topics: Adult; Androgens; Bile Acids and Salts; Biomarkers; Carnitine; Chromatography, Liquid; Dehydroepiand | 2019 |
Amino acid and fatty acid metabolomic profile during fasting and hyperinsulinemia in girls with polycystic ovarian syndrome.
Topics: Absorptiometry, Photon; Adipose Tissue; Adolescent; Amino Acids; Blood Glucose; Body Composition; Ca | 2019 |
L-Carnitine improves endocrine function and folliculogenesis by reducing inflammation, oxidative stress and apoptosis in mice following induction of polycystic ovary syndrome.
Topics: Animals; Apoptosis; Carnitine; Disease Models, Animal; Female; Follicle Stimulating Hormone; Inflamm | 2019 |
Effects of L-carnitine on Polycystic Ovary Syndrome.
Topics: Adult; Blood Glucose; Body Mass Index; Carnitine; Dehydroepiandrosterone; Female; Humans; Insulin; I | 2019 |
Metabolism alteration in follicular niche: The nexus among intermediary metabolism, mitochondrial function, and classic polycystic ovary syndrome.
Topics: Adult; Amino Acids, Branched-Chain; Carnitine; Case-Control Studies; Female; Glycolysis; Humans; Ket | 2015 |
UHPLC/Q-TOFMS-based plasma metabolomics of polycystic ovary syndrome patients with and without insulin resistance.
Topics: Adult; Biomarkers; Carnitine; Case-Control Studies; Chromatography, High Pressure Liquid; Fatty Acid | 2016 |
Plasma L-carnitine levels of obese and non-obese polycystic ovary syndrome patients.
Topics: Adolescent; Adult; Body Mass Index; Carnitine; Case-Control Studies; Cross-Sectional Studies; Female | 2017 |
Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Blood Glucose; Carnitine; Cholesterol, HDL; Dehydroepiandrosterone Sulfate; Femal | 2008 |